Revenue
234 thousand USD
2013 Q4 · USD
142 filing records in this dataset, filed from 1996-05-15 to 2024-12-18. Reported financial figures are available; chart coverage varies by period.
234 thousand USD
2013 Q4 · USD
-45.04%
2013 Q4 · %
-129 thousand USD
2013 Q4 · USD
-221 thousand USD
2013 Q4 · USD
928010 USD
673033 USD
28768055 shares
48.56% · 9.4 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2024-12-18.
Financial data available through: 2023-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
−USD 15.45 million
–
Current period
−USD 20.06 million
–
-20057302 − -15450888 = -4606414 USD
-15450888 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source-20057302 USD · 2023-01-01 – 2023-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 15.11 million
–
Current period
−USD 16.19 million
–
-16185026 − -15114241 = -1070785 USD
-15114241 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source-16185026 USD · 2023-01-01 – 2023-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 15,086
–
Current period
USD 2,420
–
2420 − 15086 = -12666 USD
15086 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source2420 USD · 2023-01-01 – 2023-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2013 2013-01-01 – 2013-12-31 | 1693335 | 1356690 Derived | 336645 | 131736 Derived | 204909 | 399618 Derived | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2013 | Revenue | 1693335 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2013 | Year over year | No prior comparable period |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2013 | Operating margin | 19.9% |
|
| 2013 | Net margin | 12.1% |
|
| 2013 | Free cash flow margin | 23.6% |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2013 | Operating cash flow | 556540 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2013 | Free cash flow | 399618 |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2013-12-31 | Liabilities / assets | Not reported |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2013 | Current assets / current liabilities | 3.11× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2013 2013-01-01 – 2013-12-31 | USD 204,909 Exact valueExact value: 204909 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 556,540 Exact valueExact value: 556540 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 156,922 Exact valueExact value: 156922 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 399,618 Calculation and evidence556540 − 156922 USD Exact free cash flow: 399618 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2014 2014-01-01 – 2014-12-31 | −USD 592,687 Exact valueExact value: -592687 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 631,162 Exact valueExact value: -631162 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 173,880 Exact valueExact value: 173880 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 805,042 Calculation and evidence-631162 − 173880 USD Exact free cash flow: -805042 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2015 2015-01-01 – 2015-12-31 | −USD 2.55 million Exact valueExact value: -2551370 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.99 million Exact valueExact value: -1989414 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 419,239 Exact valueExact value: 419239 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.41 million Calculation and evidence-1989414 − 419239 USD Exact free cash flow: -2408653 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2016 2016-01-01 – 2016-12-31 | −USD 4.22 million Exact valueExact value: -4223841 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.95 million Exact valueExact value: -2950938 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 9,343 Exact valueExact value: 9343 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.96 million Calculation and evidence-2950938 − 9343 USD Exact free cash flow: -2960281 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2020-01-01 – 2020-12-31 | −USD 8.94 million Exact valueExact value: -8941603 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 8.54 million Exact valueExact value: -8540185 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 53,127 Exact valueExact value: 53127 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 8.59 million Calculation and evidence-8540185 − 53127 USD Exact free cash flow: -8593312 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 14.29 million Exact valueExact value: -14286655 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 15.01 million Exact valueExact value: -15005298 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 22,500 Exact valueExact value: 22500 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 15.03 million Calculation and evidence-15005298 − 22500 USD Exact free cash flow: -15027798 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 15.45 million Exact valueExact value: -15450888 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 15.11 million Exact valueExact value: -15114241 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 15,086 Exact valueExact value: 15086 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 15.13 million Calculation and evidence-15114241 − 15086 USD Exact free cash flow: -15129327 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 20.06 million Exact valueExact value: -20057302 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.19 million Exact valueExact value: -16185026 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2,420 Exact valueExact value: 2420 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.19 million Calculation and evidence-16185026 − 2420 USD Exact free cash flow: -16187446 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
142 filings · 3,188 latest values · 3,188 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000922247, 922247, CTDH, CYTH, ctdh, edgar:922247
Also known as CTD HOLDINGS INC, CYCLO THERAPEUTICS, INC, CYCLO THERAPEUTICS, INC., CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC, Cyclo Therapeutics, Inc.